Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Department of Biosciences, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
J Med Chem. 2020 Oct 22;63(20):11882-11901. doi: 10.1021/acs.jmedchem.0c01100. Epub 2020 Oct 2.
Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously described analogues. SPTs have an unusual spirocyclic architecture and represent a new antibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors. They are not cross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically. The activity of the SPTs was assessed for DNA gyrase inhibition, and the antibacterial activity across Gram-positive and Gram-negative pathogens with N-linked 1,2,4-triazoles substituted on the 5-position provides the most worthwhile profile. Directed nucleophilic and electrophilic chemistry was developed to vary this 5-position with carbon, nitrogen, or oxygen substituents and explore structure-activity relationships including those around a target binding model. Compounds with favorable pharmacokinetic parameters were identified, and two compounds demonstrated cidality in a mouse model of infection.
本文报道了苯并异恶唑骨架上带有 N 连接唑取代基的螺吡喃并嘧啶酮(SPTs),与以前描述的类似物相比,其对革兰氏阳性菌具有更好的抗菌活性。SPTs 具有独特的螺环结构,代表了一种新型的细菌 DNA 拓扑异构酶 IV 抑制剂和细菌 DNA 拓扑异构酶抑制剂。它们与临床上使用的氟喹诺酮类药物和其他 DNA 拓扑异构酶/拓扑异构酶 IV 抑制剂没有交叉耐药性。评估了 SPTs 对 DNA 拓扑异构酶抑制的活性,以及具有 N 连接 1,2,4-三唑取代基的革兰氏阳性和革兰氏阴性病原体的抗菌活性,在 5 位取代基提供了最有价值的特性。开发了定向亲核和亲电化学方法来改变这个 5 位的碳原子、氮原子或氧原子取代基,并探索了构效关系,包括围绕靶结合模型的构效关系。确定了具有良好药代动力学参数的化合物,两种化合物在感染的小鼠模型中表现出杀菌作用。